Satipharm Supports HCP Education for Medicinal Cannabis

Satipharm Limited, a subsidiary of Harvest One Cannabis Inc. (TSXV: HVT) (“Satipharm” or “the Company”) has today announced it will sponsor a series of educational seminars, run by Medical Cannabis Research Australia (MCRA), to be held throughout the country in March. These seminars are an important source of clinical information for healthcare professionals and the talks will be by prescribers, pharmacists, patient advocates and other healthcare professionals.

Medicinal Cannabis was legalised in Australia in November 2016. The global legal cannabis market is expected to grow to over US$20 billion by 2020. There is good clinically-trialled evidence that cannabis-based medicines may be of benefit in chronic pain, multiple sclerosis, chemotherapy-induced nausea and vomiting as well as treatment-resistant epilepsy.

Jonathan Hartshorn, CEO Satipharm

/Public Release.